Goldacre Clashes With Pharma Over Trial Data Transparency
The pharmaceutical industry is proud of its 'forward-looking approach' to clinical trial transparency and hopes that it will help answer new research questions. But transparency campaigner Ben Goldacre has stirred controversy by saying that industry is wasting money on sharing patient-level data.
You may also be interested in...
Authors of new a study find that while most pharma companies are complying with rules for reporting trial results on the EU Clinical Trials Register, too many trials are still not being reported. They hope their newly launched online EUTrialsTracker tool might help address the situation.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.